First author, year of publication | Study design | Sample size | Sample size for RRSO | Age at time of studya, mean (range/SD)b | BRCA status (%) | Menopause status at time of RRSO (%) | Age at RRSO surgery, mean(range/SD)b | Comparator | Quality rating |
---|---|---|---|---|---|---|---|---|---|
Challberg, 2011 [33] | Cross-sectional survey design | 212 | 212 | 50(36-77) | BRCA1 & BRCA2 (58%) | Premenopausal (100%) | 41.20 (24-48) | Non-exposed and previous users | Low |
Chapman, 2011 [37] | Cross-sectional survey design | 51 | 51 | 49 (36-54) | BRCA1 (63%) & BRCA2 (37%) | Premenopausal (47%) & Postmenopausal (53%) | 46 (31–68) | Non-exposed | Low |
Eisen, 2008 [21] | Matched case control study | 472 | 136 | NS | BRCA1 (100%) | Premenopausal (100%) | 42.45 (28 – 52)c | Control (no outcome) | High |
Finch, 2011 [38] | Prospective cohort study | 114 | 114 | 53(42-74) | BRCA1 (51%) & BRCA2 (49%) | Premenopausal (66%) & Postmenopausal (34%) | 47.50 (35-69) | Non-exposed, baseline | Low |
Gabriel, 2008 [28] | Retrospective cohort study | 73 | 73 | NS | BRCA1 (64%) & BRCA2 (38%) | Premenopausal (NS) & Postmenopausal (NS) | 42 (29.5-59.2) | Non-exposed | Low |
Garcia, 2015 [30] | Retrospective chart review | 225 | 225 | NS | BRCA1 & 2 (100%) | Premenopausal (NS) & Postmenopausal (NS) | 50 (31-80) | Non-exposed | Low |
Heiniger, 2014 [29] | Matched prospective cohort design | 233 | 38 | NS | BRCA1 & 2 (16.7%) | Premenopausal (NS) & Postmenopausal (NS) | NS | Non-exposed and previous users | Low |
Johansen, 2016 [36] | Retrospective cohort study | 1522 | 294 | 54(33-83) | NSd | Premenopausal (NS) & Postmenopausal (NS) | 48(31-76) | Non-exposed | Low |
Kotsopoulos, 2016 [31] | Matched case control study | 864 | 210 | NS | BRCA 1 (100%) | Premenopausal (NS) & Postmenopausal (NS) | 42.75(28-53)c | Control (no outcome) | Low |
Madalinska, 2006 [34] | Cross-sectional survey design | 450 | 450 | 46 ± 6 (range34-59) | BRCA1 & 2 (48%) | Premenopausal (100%) | 43 ± 6 | Non-exposed | High |
Michelsen, 2009 [35] | Cross-sectional survey design | 1956 | 326 | 54.4(8.9) | BRCA1 & 2 (20%) | Premenopausal (NS) & Postmenopausal (NS) | 48 ± 7.8 | Non-exposed | High |
Rebbeck, 2005 [20] | Prospective cohort study | 462 | 155 | 42.7(37-78) | BRCA1 (70%) & BRCA2 (30%) | Premenopausal (NS) & Postmenopausal (NS) | NS | Non-exposed | High |
Tucker, 2016 [32] | Cross-sectional survey design | 119 | 119 | NS | BRCA1 (8.40%) & BRCA2 (11.70%) | Premenopausal (43%) & Postmenopausal (57%) | 50(33-69) | Non-exposed | Low |